GHK‑Cu / BPC‑157 / TB‑500
US$ 23.49
fda warning unapproved peptide products bpc-157 tb-500 cjc-1295 The problem: Hype is outrunning the evidence fda warning unapproved peptide products
Description
LAST UPDATED 2026-05-19
Common targets include interleukin-23 (IL-23) and interleukin-12 (IL-12)
Injectable B12 bypasses absorption issues and is first-line treatment for malabsorption conditions, whilst oral doses of 1,0002,000 g daily may suit dietary deficiency without malabsorption
[DOI] [PubMed] [Google Scholar] 52.Schmidt W., Prommer N
